Neuraxis, Inc. Cash Flow Conversion Efficiency
Neuraxis, Inc. cash flow conversion efficiency. Based on the latest financial reports, Neuraxis, Inc. (NRXS) has a cash flow conversion efficiency ratio of -0.214x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.23 Million) by net assets ($5.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Neuraxis, Inc. (2020–2025)
Cash flow conversion efficiency of Neuraxis, Inc. from 2020 to 2025. This chart illustrates how Neuraxis, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Neuraxis, Inc. (NRXS) stock price for real-time trading data and today's change.
Neuraxis, Inc. Cash Flow Conversion Ratio Explained
Neuraxis, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Neuraxis, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuraxis, Inc. ranked by their cash flow conversion efficiency. Also see NRXS stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AMTD IDEA Group
NYSE:AMTD
|
0.003x |
|
Appeninn Vagyonkezelo Holding Nyilvanosan Mukodo Reszvenytarsasag
F:0AP
|
0.160x |
|
Prozone Realty Limited
NSE:PROZONER
|
0.044x |
|
Maywood Acquisition Corp. Unit
NASDAQ:MAYAU
|
-0.002x |
|
Escar Turizm Tasimacilik Ticaret AS
IS:ESCAR
|
0.012x |
|
Hun Yenilenebilir Enerji Uretim AS
IS:HUNER
|
0.014x |
|
Oroco Resource Corp
V:OCO
|
-0.014x |
|
DT Cloud Star Acquisition Corporation Units
NASDAQ:DTSQU
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Neuraxis, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Neuraxis, Inc. from 2020 to 2025. Review NRXS FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.40 Million | $-6.43 Million | -1.892x | +35.84% |
| 2024-12-31 | $2.07 Million | $-6.10 Million | -2.949x | -161.82% |
| 2023-12-31 | $-1.40 Million | $-6.69 Million | 4.770x | +1057.01% |
| 2022-12-31 | $-5.57 Million | $-2.30 Million | 0.412x | -84.76% |
| 2021-12-31 | $-825.66K | $-2.23 Million | 2.706x | +207.46% |
| 2020-12-31 | $1.64 Million | $-4.14 Million | -2.518x | -- |
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional … Read more